BiotechTube

rFVIIIFc

ApprovedCompleted
0 watching 0 views this week🔥 Hot
84
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hemophilia A With Inhibitors

Conditions

Hemophilia A With Inhibitors

Trial Timeline

Dec 8, 2017 → Feb 16, 2021

NCT ID
NCT03093480

About rFVIIIFc

rFVIIIFc is a approved stage product being developed by Swedish Orphan Biovitrum for Hemophilia A With Inhibitors. The current trial status is completed. This product is registered under clinical trial identifier NCT03093480. Target conditions include Hemophilia A With Inhibitors.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (3)

NCT IDPhaseStatus
NCT03093480ApprovedCompleted
NCT02502149Phase 3Completed
NCT02234323Phase 3Completed

Competing Products

20 competing products in Hemophilia A With Inhibitors

See all competitors
ProductCompanyStageHype Score
EmicizumabChugai PharmaceuticalPhase 3
77
EmicizumabChugai PharmaceuticalPhase 3
77
Emicizumab + rFVIIa + aPCCChugai PharmaceuticalPhase 3
77
Human Coagulation Factor VIIIChugai PharmaceuticalPhase 3
77
EmicizumabChugai PharmaceuticalPhase 3
77
Emicizumab + Factor VIII (FVIII)Chugai PharmaceuticalPhase 3
77
EmicizumabRochePhase 3
77
HEMLIBRAJohnson & JohnsonPre-clinical
23
EmicizumabRochePhase 3
77
EmicizumabRocheApproved
85
EmicizumabRochePhase 3
77
SPK-8011QQRochePhase 1/2
41
NXT007RochePhase 1/2
41
Emicizumab InjectionRochePhase 2
52
Bypassing Agents + FVIII ReplacementRochePre-clinical
23
PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086PfizerPhase 2
51
Nonacog Alfa (Genetical Recombination)PfizerPre-clinical
22
Refacto AFPfizerPre-clinical
22
PF-06838435/ fidanacogene elaparvovecPfizerPhase 3
76
ReFacto AFPfizerPhase 3
76

Other Products from Swedish Orphan Biovitrum

Recombinant coagulation factor (rFVIIIFc)Approved
84
AnakinraApproved
84
Efanesoctocog alfaApproved
84
Kepivance (Palifermin)Approved
84
Emapalumab-Lzsg 5 MG/ML [Gamifant]Approved
84